Cannabinoids are a diverse group of chemical compounds that interact with the body’s endocannabinoid system (ECS), and they are generally classified into three main types based on their source and chemical structure: phytocannabinoids (from plants), endocannabinoids (produced by the body), and synthetic cannabinoids (lab-made).
Phytocannabinoids are naturally occurring in the Cannabis sativa plant and include compounds like THC, which is psychoactive and known for pain relief and appetite stimulation, and CBD, which is non-psychoactive and often used for inflammation, anxiety, and seizures. Other notable phytocannabinoids include CBN (a sedative byproduct of THC), CBG (antibacterial and anti-inflammatory), CBC (neuroprotective), and THCV, which is psychoactive at high doses and may suppress appetite.
Endocannabinoids, such as anandamide (AEA) and 2-AG, are produced within the human body and help regulate mood, sleep, pain, appetite, and immune responses. They bind to CB1 receptors in the brain and CB2 receptors in the immune system to help maintain physiological balance.
Synthetic cannabinoids mimic or block natural cannabinoids. Medically approved examples include dronabinol and nabilone, which are used to treat nausea and stimulate appetite, while illicit variants like Spice/K2 are often dangerous due to their potency and unpredictable effects.
Cannabinoids vary in their psychoactivity: THC and THCV (at high doses) are psychoactive, while CBD, CBG, CBC, and CBN generally are not. Their effects depend on how they interact with cannabinoid receptors, influencing processes like inflammation, pain, mood, and immune response.
Cannabinoids used for IV therapy are only the primarily non-psychoactive compounds derived from the cannabis plant, and they have garnered significant attention for their potential therapeutic benefits. While traditionally consumed orally or via inhalation, intravenous (IV) administration of cannabinoids is emerging as a method to enhance its efficacy and bioavailability. This article explores the known benefits of IV cannabinoids infusions, supported by current research and clinical observations.
Enhanced Bioavailability and Rapid Onset
One of the primary advantages of IV cannabinoids infusion is the direct delivery into the bloodstream, bypassing the digestive system. This method ensures nearly 100% bioavailability, allowing for higher concentrations of cannabinoids to reach target tissues more efficiently than oral administration. This also allows the pure cannabinoid into the bloodstream without alteration by the liver first. Consequently, patients may experience therapeutic effects more rapidly, which is particularly beneficial for acute symptom management.
Pain Relief and Anti-Inflammatory Effects
Cannabinoids are renowned for their analgesic and anti-inflammatory properties. Studies suggest that cannabinoids interact with the endocannabinoid system to modulate pain perception and reduce inflammation. IV administration can provide lasting relief for individuals suffering from chronic pain conditions such as arthritis, fibromyalgia, and neuropathy. By delivering cannabinoids directly into the bloodstream, IV infusions may offer a more immediate and potent effect compared to other delivery methods.
Anxiety and Stress Reduction
Research indicates that cannabinoids have anxiolytic properties, potentially aiding individuals with anxiety disorders. Cannabinoids’ interaction with serotonin receptors in the brain may help regulate mood and alleviate stress. IV infusions can facilitate a rapid onset of these calming effects, providing timely relief for those experiencing heightened anxiety or panic episodes. PMC
Neuroprotective Properties
Emerging evidence suggests that cannabinoids possess neuroprotective qualities, which may be beneficial in managing neurological disorders such as multiple sclerosis, Parkinson’s disease, and traumatic brain injury. By reducing oxidative stress and inflammation, cannabinoids may support neuronal health and function. IV administration ensures optimal delivery to the central nervous system, potentially enhancing these neuroprotective effects. PMC
Improved Sleep Quality
Cannabinoids have been associated with promoting better sleep by addressing underlying factors such as anxiety and pain that often disrupt rest. IV infusions can provide a rapid calming effect, aiding individuals who struggle with insomnia or other sleep disorders. By facilitating relaxation and reducing discomfort, cannabinoids may contribute to more restful and restorative sleep.
IV Cannabinoid Source – Pico IV
Pico IV is a sterile, intravenous therapy that incorporates a blend of cannabinoids designed to maximize therapeutic benefits through the entourage effect. The formulation includes the following cannabinoids:
- CBD (Cannabidiol): The primary non-psychoactive compound known for its potential anti-inflammatory, analgesic, and anxiolytic properties.
- CBG (Cannabigerol): Often referred to as the “mother cannabinoid,” it may support bone health and exhibit neuroprotective effects.
- CBN (Cannabinol): A mildly psychoactive compound that may promote relaxation and aid in sleep.
- CBC (Cannabichromene): Known for potential anti-inflammatory and neuroprotective properties.
- CBDa (Cannabidiolic Acid): The acidic precursor to CBD, which may have anti-inflammatory and neuroprotective effects.
- CBGa (Cannabigerolic Acid): The acidic precursor to CBG, which may possess antibacterial properties.
It’s important to note that Pico IV’s formulation is THC-free, ensuring it is non-psychoactive and does not produce a “high” sensation. The product is derived from U.S.-grown hemp and is legal across the United States. However, access to Pico IV is restricted to licensed medical providers, and it is not available for over-the-counter purchase.
For more detailed information or to locate a provider, you can visit the official Pico IV website.
Considerations and Safety
While IV cannabinoid therapy offers promising benefits, it is essential to approach this treatment under the guidance of qualified healthcare professionals. Our infusion nurses have extensive experience with a wide variety of infusions and excel at safe administration and monitoring of IV therapies.
Author
Scott Rollins, MD, is Board Certified with the American Board of Family Practice and the American Board of Anti-Aging and Regenerative Medicine. He specializes in bioidentical hormone replacement for men and women, thyroid and adrenal disorders, fibromyalgia and other complex medical conditions. He is founder and medical director of the Integrative Medicine Center of Western Colorado (www.imcwc.com) and Bellezza Laser Aesthetics (www.bellezzalaser.com). Call (970) 245-6911 for an appointment or more information.
